OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Sun on Managing TEAEs of Tisotumab Vedotin in Recurrent/Metastatic HSNCC

July 16th 2024

Lova Sun, MD, MSCE, discussions safety implications observed from part C of the phase 2 innovaTV 207 trial.

Dr Fayette on the Efficacy of Petosemtamab Plus Pembrolizumab in Metastatic HNSCC

July 15th 2024

Jerôme Fayette, MD, PhD, discusses findings from a trial of frontline petosemtamab plus pembrolizumab in patients with recurrent/metastatic HNSCC.

Dr Gong on the Importance of Molecular Profiling in mCRPC

July 15th 2024

Jun Gong, MD, discusses the importance of molecular profiling when determining optimal treatments for patients with mCRPC.

Dr Klisovic on the Early Use of JAK Inhibitors in Younger Patients With Low-Risk Myelofibrosis

July 15th 2024

Rebecca Klisovic, MD, discusses the early use of JAK inhibitors to treat younger patients with low-risk, newly diagnosed myelofibrosis.

Dr Kirtane on the Design of a Phase 1b Trial of Tbio4101 Plus Pembrolizumab in HNSCC

July 15th 2024

Kedar Kirtane, MD, discusses the design of a phase 1b trial evaluating the TIL Tbio-4101 plus pembrolizumab in patients with advanced HNSCC.

Dr Garje on the Benefits of Multimodal Treatment in Small Cell Bladder Cancer

July 15th 2024

Rohan Garje, MD, discusses the benefits of a multimodal approach for patients with small cell bladder cancer.

Dr Ma on Questions Regarding Treatment Sequencing in CDK4/6 Inhibitor–Resistant Breast Cancer

July 15th 2024

Cynthia Ma, MD, PhD, discusses unanswered questions regarding treatment sequencing for patients who develop CDK4/6 inhibitor–resistant breast cancer.

Dr Roy on Limitations of the Pathway Trial Evaluating PGS and Survival in Breast Cancer

July 15th 2024

Arya Mariam Roy, MBBS discusses limitations of the Pathway trial evaluating the association between polygenic scores and survival outcomes in patients with breast cancer.

Dr Semaan on Liquid Biopsy Epigenomic Profiling for the Detection of Sarcomatoid RCC

July 12th 2024

Karl Semaan, MD, MSc, discusses the utility of liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma.

Dr McGregor on the Data for Abemaciclib in Advanced ccRCC

July 12th 2024

Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib in clear cell renal cell carcinoma.

Dr Grimm on Unmet Needs After Progression to mCRPC Following ARPI Plus Chemo

July 12th 2024

Marc-Oliver Grimm, MD discusses the clinical implications, short comings, and future steps following a post-hoc analysis from the phase 3 ARASENS trial.

Dr Chao on the Correlation Between Broad-Spectrum Antibiotics and Early-Onset CRC

July 11th 2024

Chun Chao, PhD, MS, discusses the association between the use of broad-spectrum antibiotics and the risk of developing early-onset colorectal cancer.

Dr Sekeres on Outcomes With Imetelstat in Transfusion-Dependent MDS

July 11th 2024

Mikkael A. Sekeres, MD, discusses a subgroup analysis of treatment with imetelstat in patients with low-to intermediate-1–risk myelodysplastic syndrome.

Dr Biran on the DREAMM-7 Trial in Multiple Myeloma

July 11th 2024

Noa Biran, MD, discusses the implications of findings from the phase 3 DREAMM-7 trial in multiple myeloma.

Dr Mehra on the Implications of the E3311 Trial in HPV+ Oropharynx Cancer

July 11th 2024

Ranee Mehra, MD, discusses long-term follow-up data from the phase 2 E3311 trial in patients with HPV-associated oropharynx cancer.

Dr Pal on the Preliminary Efficacy of DFF332 in Advanced ccRCC

July 11th 2024

Sumanta Kumar Pal, MD, FASCO, discusses preliminary findings from a phase 1 dose-escalation study of DFF332 in patients with advanced ccRCC.

Dr Garfall on Long-Term Data for Teclistamab in Relapsed/Refractory Myeloma

July 11th 2024

Alfred L. Garfall, MD, MS discusses updated long-term data for teclistamab in patients with relapsed/refractory multiple myeloma.

Dr Braun on Selecting Immune Checkpoint Inhibitor–Based Combos in ccRCC

July 11th 2024

David Braun, MD, PhD discusses the selection of immune checkpoint inhibitor use in clear cell renal cell carcinoma

Dr Hunter on the Management Ruxolitinib-Associated AEs in Myelofibrosis

July 11th 2024

Anthony M. Hunter, MD, discusses challenges associated with ruxolitinib-based toxicities in patients with myelofibrosis.

Dr Krishnan on Patient Characteristics Associated With Early Relapse in Multiple Myeloma

July 11th 2024

Amrita Krishnan, MD, discusses the characteristics and factors associated with a higher risk of early relapse for patients with multiple myeloma.